FILING ANALYSIS · MONDAY, OCTOBER 5
NRX Pharmaceuticals, Inc. NRXP — 8-K: Entry into a Material Definitive Agreement
positive
NRx Pharmaceuticals' subsidiary NRx Defense Systems has been awarded an $11.2 million contract by DARPA to conduct a clinical trial for the treatment of treatment-resistant depression, with the contract having an 18-month performance period and providing for payment upon achievement of specified program milestones.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →